Relapse following clozapine withdrawal: Effect of neuroleptic drugs and cyproheptadine

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 176-187

  Meltzer, Herbert Y ^a   Lee, Myung A ^a   Ranjan, Rakesh ^a   Mason, Ellen A ^a   Cola, Philip A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Clozapine; Dopamine; Psychosis; Schizophrenia; Serotonin

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYPROHEPTADINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; SEROTONIN ANTAGONIST;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYPROHEPTADINE; FEMALE; HUMANS; MALE; PERPHENAZINE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0029916129     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245619     Document Type: Article

References (67)

1. Alphs LD, Lee HS (1991) Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 52:346-348
2. Bacher NM, Sanzone MM, Kamp B (1994) Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine. J Clin Psychopharmacol 14:424-425
3. Borison RL, Diamond BI, Sinha D, Gupta RP, Ajboye PA (1988) Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24:260-263
4. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20-26
5. 3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology 106: 479-483
6. 3 receptor mRNA levels. Neuropharmacology 32:901-907
7. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
8. Davis KL, Rosenberg GS (1979) Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 14:699-703
9. Diamond BI, Borison RL (1986) Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull 26:900-905
10. Dickson R, Williams R, Dalby JT (1994) Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 39:184
11. Ekblom B, Haggstrom JE (1974) Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 16:945-957
12. Ekblom B, Eriksson K, Lindström LH (1984) Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 83:293-294
13. Eklund K (1987) Supersensitivity and clozapine withdrawal. Psychopharmacology 91:135
14. Endicott J, Spitzer RL (1978) A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35:837-844
15. Fink H, Morgenstern R, Oelssner W (1979) Psychotomimetics potentiate locomotor hyperactivity induced by dopaminergic drugs. Pharmacol Biochem Behav 11:479-182
16. Fischer-Cornelssen KA, Ferner UJ, Steiner H (1974) Multifokale Psychopharmaka-prufung ("Multihospital Trial"). Arzneimittelforschung 24:1706-1724
17. Garrison JC (1990) Histamine, bradykinesia, 5-hydroxytryptamine, and their antagonists. In Gelenberg AJ, Doller JC (1979) Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry 40:238-240
18. Gerlach J, Koppelhus P, Helweg E, Manrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial. Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410-424
19. Gilbert PL, Harris WJ, McAdams LA, Jeste DA (1995) Neuroleplic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 52:173-188
20. Glovinsky D, Kirch DG, Wyatt RJ (1992) Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry 31:968-970
21. Halperin R, Guerin Jr JJ, Davis KL (1989) Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology 98:386-391
22. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993) Relationship between clinical efficacy and clozapine plasma concentrations in schizophrenia: effect of smoking. J Clin Psychopharmacol 13:383-390
23. Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10[3]:388-398
24. Hogarty G, Ulrich R, Mussare F, Aristigueta N (1976) Drug discrimination among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst 37:494-500
25. Ichikawa J, Meltzer HY (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J Pharmacol Exp Ther 256:348-357
26. 2C/2A receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res (in press)
27. Ichikawa J, Meltzer HY (1992) Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vitro in rat striatum and nucleus accumbens. J Neurochem 58:2285-2291
28. Idzikowski C, Cowen PJ, Mutt D, Mills FJ (1987) The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology 93:416-420
29. Idzikowski C, Mills FJ, James RJ (1991) A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharmacol 31:193-196
30. Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
31. Krupp P, Barnes P (1989) Leponex®-associated granulocytopenia: a review of the situation. Psychopharmacology (Suppl) 99:S118-S121
32. 1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264:1262-1267
33. Lee MA, Thompson P, Meltzer HY (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55[Suppl B]:82-87
34. Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ (1995) Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol 10:67-72
35. Linszen DH, Dinegemans PM, Lenoir ME, Nugter MA, Scholte WF, Van der Does AJW (1994) Relapse criteria in schizophrenic disorders: difference perspectives. Psychiatry Res 54:273-281
36. Llorca DM, Wolf MA, Laneon C, Bougerol T (1993) Efficcaté comparée de la bromocriptine, de la carbamazépine et de la cyproheptadine, schizophrènes chroniques résistants. Encephale 19:565-571
37. Luchins DJ, Freed WJ, Wyatt RJ (1980) The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 137: 1395-1398
38. 2 receptor density in rat cerebral cortex. Life Sci 45:1397-1406
39. Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287
40. Meltzer HY (1992a) Dimensions of outcome with clozapine. Br J Psychiatry 160 [Suppl 17]:46-53
41. Meltzer HY (1992b) Treatment of the neuroleptic non-responsive schizophrenic patients. Schizophr Bull 18:515-542
42. Miller DD, Flaum M, Arndt S, Fleming F, Andreasan NC (1994) Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 11:11-20
43. Miller RJ, Hiley CR (1974) Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248:596-597
44. Nash JF, Meltzer HY, Gudelsky GA (1990) Effect of 3,4-methylenedioxymethamphetamine on 3,4-di-hydroxyphenylalanine in the striatum and nucleus accumulation in the striatum and nucleus accumbens. J Neurochem 54:1062-1067
45. Neylan TC, Van Kammen DP, Kelley ME, Peters JL (1992) Sleep in schizophrenic patients on and off haloperidol therapy: clinically stable versus relapsed patients. Arch Gen Psychiatry 49:643-649
46. Overall JE, Gorham D (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:149-165
47. Parsa MA, Al-Lanhram Y, Ramirez LF, Meltzer HY (1993) Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 13:154-155
48. Perényi A, Kunsz E, Bagdy G (1985) Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology 86:244
49. Perry PJ, Miller DD, Arndt S, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231-235
50. Prien RF, Cole J, Belkin N (1968) Relapse in chronic schizophrenics following abrupt withdrawal of tranquilizing medication. Br J Psychiatry 115:679-686
51. Rupniak NMJ, Kilpatrick G, Hall MD, Jenner P, Marsden CD (1984) Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology 84:512-519
52. Schremmer C, Morgenstern R, Fink H, Oh T (1990) Atypical neurlopetics suppress dopaminergic behavioral supersensitivity. Psychopharmacology 100:399-403
53. 2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 101:568-569
54. Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, Kurtz NM, Cutler NR (1995) Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull (in press)
55. Shopsin B, Klein H, Aaronson M, Collora M (1979) Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients. Arch Gen Psychiatry 36:657-664
56. Shore D, Matthew S, Cott J, Lieberman JA (1995) Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 21:333-338
57. Silver H, Blacker M, Weller MP, Lerer B (1989) Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 25:502-504
58. Silver H, Blacker M, Weller MP, Lerer B (1991) Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo controlled study. Biol Psychiatry 30:523-525
59. 2 receptor antagonists; detection by ambulatory EEG recording and automatic sleep stage analysis. J Psychopharmacol 3:125-129
60. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691
61. Specchio LM, Puca FM, Genco S, Candeliere G, Galeone D, Dammacco F (1976) Effectti della ciproheptadine sul sonno dellumo normale. Boll Soc Ital Biol Sper 52:1789-1793
62. 2 antagonist, enhances slow wave sleep in rats. 17th Congress of Collegium Internationale Neuropharmacologicum, Kyoto, Japan, Abstract 1394
63. Van Rizen H (1972) Different central effects of the 5-HT antagonists mianserin and cyproheptadine. Arch Int Pharmacodyn 198:256-269
64. Vencovsky E, Peterova E, Baudis P (1975) Comparison of therapeutic effect of clozapine and chlorpromazine. Ceskoslovenska Psychiatric 71:21-26
65. 2) receptors in the rat brain. Brain Res 487:288-298
66. Yamamoto BK, Pehek EA, Meltzer HY (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55 [Suppl B]:8-14
67. Zapletálek M, Preiningerova O, Hanus H (1980) Does clozapine cause dependence? (German) Agressologie 21[A]:19-22